FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994682716> ?p ?o ?g. }

• W2994682716 endingPage "47" @default.
• W2994682716 startingPage "39" @default.
• W2994682716 abstract "Sodium glucose cotransporter 2 (SGLT2) inhibitors are established antidiabetic drugs with proven cardiovascular benefit. Although growing evidence suggests beneficial effects on myocardial remodeling, fluid balance and cardiac function, the impact of empagliflozin initiated early after acute myocardial infarction (AMI) has not been investigated yet. Therefore, the impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY) trial was designed to investigate the efficacy and safety of empagliflozin in diabetic and non-diabetic patients after severe AMI. Within a multicenter, randomized, double-blind, placebo-controlled, phase 3b trial we will enroll patients with AMI and characteristics suggestive of severe myocardial necrosis are randomized in a 1:1 ratio to empagliflozin (10 mg once daily) or matching placebo. The primary endpoint is the impact of empagliflozin on changes in NT-proBNP within 6 months after AMI. Secondary endpoints include changes in echocardiographic parameters, levels of ketone body concentrations, HbA1c levels and body weight, respectively. Hospitalization rate due to heart failure or other causes, the duration of hospital stay and all-cause mortality will be assessed as exploratory secondary endpoints. The EMMY trial will test empagliflozin in patients with AMI regardless of their diabetic status. The EMMY trial may therefore underpin the concept of SGLT2 inhibition to improve cardiac remodeling, pre-and afterload reduction and cardiac metabolism regardless of its antidiabetic effects. Results will provide the rationale for the conduct of a cardiovascular outcome trial to test the effect of empagliflozin in patients with AMI." @default.
• W2994682716 created "2019-12-26" @default.
• W2994682716 creator A5003796858 @default.
• W2994682716 creator A5008305293 @default.
• W2994682716 creator A5009556015 @default.
• W2994682716 creator A5009903680 @default.
• W2994682716 creator A5010355045 @default.
• W2994682716 creator A5014962055 @default.
• W2994682716 creator A5017726010 @default.
• W2994682716 creator A5018883903 @default.
• W2994682716 creator A5020152746 @default.
• W2994682716 creator A5022384816 @default.
• W2994682716 creator A5030107346 @default.
• W2994682716 creator A5032226709 @default.
• W2994682716 creator A5034251192 @default.
• W2994682716 creator A5040691180 @default.
• W2994682716 creator A5051530545 @default.
• W2994682716 creator A5051718614 @default.
• W2994682716 creator A5055700473 @default.
• W2994682716 creator A5056821482 @default.
• W2994682716 creator A5067997007 @default.
• W2994682716 creator A5072768076 @default.
• W2994682716 creator A5073891818 @default.
• W2994682716 creator A5077137975 @default.
• W2994682716 date "2020-03-01" @default.
• W2994682716 modified "2023-10-16" @default.
• W2994682716 title "Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial" @default.
• W2994682716 cites W2023820364 @default.
• W2994682716 cites W2081130499 @default.
• W2994682716 cites W2111183899 @default.
• W2994682716 cites W2118613762 @default.
• W2994682716 cites W2146264128 @default.
• W2994682716 cites W2179931293 @default.
• W2994682716 cites W2253712555 @default.
• W2994682716 cites W2328718696 @default.
• W2994682716 cites W2471327176 @default.
• W2994682716 cites W2612486405 @default.
• W2994682716 cites W2618557766 @default.
• W2994682716 cites W2626446274 @default.
• W2994682716 cites W2772835527 @default.
• W2994682716 cites W2800277129 @default.
• W2994682716 cites W2808816873 @default.
• W2994682716 cites W2894993577 @default.
• W2994682716 cites W2897621296 @default.
• W2994682716 cites W2900413769 @default.
• W2994682716 cites W3152272963 @default.
• W2994682716 cites W4249896096 @default.
• W2994682716 doi "https://doi.org/10.1016/j.ahj.2019.12.004" @default.
• W2994682716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31901799" @default.
• W2994682716 hasPublicationYear "2020" @default.
• W2994682716 type Work @default.
• W2994682716 sameAs 2994682716 @default.
• W2994682716 citedByCount "40" @default.
• W2994682716 countsByYear W29946827162020 @default.
• W2994682716 countsByYear W29946827162021 @default.
• W2994682716 countsByYear W29946827162022 @default.
• W2994682716 countsByYear W29946827162023 @default.
• W2994682716 crossrefType "journal-article" @default.
• W2994682716 hasAuthorship W2994682716A5003796858 @default.
• W2994682716 hasAuthorship W2994682716A5008305293 @default.
• W2994682716 hasAuthorship W2994682716A5009556015 @default.
• W2994682716 hasAuthorship W2994682716A5009903680 @default.
• W2994682716 hasAuthorship W2994682716A5010355045 @default.
• W2994682716 hasAuthorship W2994682716A5014962055 @default.
• W2994682716 hasAuthorship W2994682716A5017726010 @default.
• W2994682716 hasAuthorship W2994682716A5018883903 @default.
• W2994682716 hasAuthorship W2994682716A5020152746 @default.
• W2994682716 hasAuthorship W2994682716A5022384816 @default.
• W2994682716 hasAuthorship W2994682716A5030107346 @default.
• W2994682716 hasAuthorship W2994682716A5032226709 @default.
• W2994682716 hasAuthorship W2994682716A5034251192 @default.
• W2994682716 hasAuthorship W2994682716A5040691180 @default.
• W2994682716 hasAuthorship W2994682716A5051530545 @default.
• W2994682716 hasAuthorship W2994682716A5051718614 @default.
• W2994682716 hasAuthorship W2994682716A5055700473 @default.
• W2994682716 hasAuthorship W2994682716A5056821482 @default.
• W2994682716 hasAuthorship W2994682716A5067997007 @default.
• W2994682716 hasAuthorship W2994682716A5072768076 @default.
• W2994682716 hasAuthorship W2994682716A5073891818 @default.
• W2994682716 hasAuthorship W2994682716A5077137975 @default.
• W2994682716 hasConcept C111566952 @default.
• W2994682716 hasConcept C126322002 @default.
• W2994682716 hasConcept C134018914 @default.
• W2994682716 hasConcept C142724271 @default.
• W2994682716 hasConcept C164705383 @default.
• W2994682716 hasConcept C168563851 @default.
• W2994682716 hasConcept C203092338 @default.
• W2994682716 hasConcept C204787440 @default.
• W2994682716 hasConcept C27081682 @default.
• W2994682716 hasConcept C2775887513 @default.
• W2994682716 hasConcept C2777180221 @default.
• W2994682716 hasConcept C2778198053 @default.
• W2994682716 hasConcept C500558357 @default.
• W2994682716 hasConcept C555293320 @default.
• W2994682716 hasConcept C71924100 @default.
• W2994682716 hasConceptScore W2994682716C111566952 @default.
• W2994682716 hasConceptScore W2994682716C126322002 @default.
• W2994682716 hasConceptScore W2994682716C134018914 @default.

• next